COVID‐19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group
- 24 April 2024
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (3) , e14758
Abstract
Background: Data on the risk factors and outcomes for pediatric patients with SARS‐CoV‐2 infection (COVID‐19) following hematopoietic stem cell transplantation (HSCT) are limited.Objectives: The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID‐19 infection.Method: In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID‐19 between March 2020 and August 2022.Results: The median time from HSCT to COVID‐19 infection was 209.0 days (IQR, 111.7–340.8; range, 0–3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID‐19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS‐C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID‐19‐related mortality.Conclusion: While COVID‐19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS‐C or LRTD.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19JAMA Oncology, 2023
- Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)Annals of Hematology, 2022
- Multisystem Inflammatory Syndrome in Children (MIS-C)Current Allergy and Asthma Reports, 2022
- Characterization of COVID‐19 disease in pediatric oncology patients: The New York‐New Jersey regional experiencePediatric Blood & Cancer, 2020
- Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS‐CoV‐2 pandemicPediatric Blood & Cancer, 2020
- COVID‐19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH)Pediatric Blood & Cancer, 2020
- Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research NetworksEuropean Journal of Pediatrics, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in ChinaJAMA Network Open, 2020
- Clinical features and treatment of COVID‐19 patients in northeast ChongqingJournal of Medical Virology, 2020